Here in the Division of Pulmonary, Critical Care and Sleep Medicine at Mount Sinai, the last few years have been extraordinary. In 2014 we opened the Mount Sinai-National Jewish Health Respiratory Institute, http://nationaljewish.mountsinai.org, and created a model for delivering patient centered, multidisciplinary, state-of-the-art care for patients with simple and complex respiratory diseases, which also includes physicians from Gastroenterology, Cardiology and Rheumatology. Of particular note for you, for out-of-town referrals, we provide comprehensive multi-day visits for the evaluation and treatment of undiagnosed respiratory diseases.
We also have also the largest sarcoidosis program in the northeast and a long tradition of sarcoidosis research and treatment. Adam Morgenthau, MD, Director of the Sarcoidosis Clinic at Mount Sinai, sees approximately 100 patients with sarcoidosis a month and has tremendous experience in diagnosis and management of sarcoidosis given such an extensive patient base.
Our Lung Cancer Research Program has identified key molecular pathways of adenocarcinoma from indolent tumor to metastatic tumor and this has become increasingly important as efforts to detect early stage lung cancers begins to pay off. Our pioneering screening program run by Claudia Henschke, MD, PhD, Professor of Radiology, has shown that CT scans can find 85 percent of lung cancers in their earliest, most treatable, stages and with greater accuracy. This screening program has now been implemented internationally as the IELCAP consortium.
At Mount Sinai we are one of only two sites in the city for a new NIH multi-center trial (PETAL) for acute lung injury. We hope that these studies and the close collaborative relationship with Emergency Medicine within the trials will identify new opportunities for the prevention and treatment of adult respiratory distress syndrome.